Work

Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.4_suppl.tps250

Authors: Evan Y. Yu, Anthony M. Joshua, Neal D. Shore, Gero Kramer, Haixia Hu, Christian Heinrich Poehlein, Charles Schloss, Johann S. De Bono

Institutions: University of Washington, St Vincent's Hospital Sydney, Carolina Urologic Research Center, Medical University of Vienna, Merck & Co., Inc., Rahway, NJ, USA (United States), Royal Marsden NHS Foundation Trust, Royal Marsden Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Medical Research Council

Award: G5773843864

OpenAlex ID: W4391302996

Cites:

Cited by: 3

Related to: 10